Pharmaceutical management of the childhood glaucomas

Bibliography

• KHAW PT, FREEDMAN S, GANDOFFI S: Cases in contro- versy: management of congenital glaucoma. J. Glaucoma (1999) 8:81–85.
   PubMed Web of Science ®Google Scholar
• ••An excellent discussion of current controversies in manage-ment of congenital glaucoma.
   Google Scholar
• PASSO MS, PALMER EA, VAN BUSKIRK EM: Plasma tinaolol in glaucoma patients. Ophthalmology (1984) 91(11):1361–1363.
   PubMed Web of Science ®Google Scholar
• ••Key historic article demonstrating inverse relationshipbetween drug level and age of patient.
   Google Scholar
• ZIMMERMAN TJ, KOONER KS, KANDARAKIS AS, ZIEGLER LP: Improving the therapeutic index of topically applied ocular drugs. Arch. Ophthalmol. (1984) 102:551–553.
   PubMed Web of Science ®Google Scholar
• Becker-Shaffer's Diagnosis and Therapy of the Glaucomas (7th Edition). Stamper RL, Lieberman MF, Drake MV (Eds.), Mosby, St Louis, USA (1999).
   Google Scholar
• MCMAHON CD, HEATHERINGTON J, HOSKINS HD et al.: Tirnolol and paediatric glaucomas. Ophthalmology (1981) 88:249–253.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN TJ: Safety and efficacy of timolol inpaediatric glaucoma. Surv. Ophthalmol. (1983) 28(Suppl.):262–264.
   Google Scholar
• •Excellent historic review
   Google Scholar
• HOSKINS HD: Clinical experience with timolol in childhood glaucomas. Arch. Ophthalmol. (1985) 103(Suppl.):1163–1165.
   Google Scholar
• BOGER WP, WALTON DS: Tirnolol in uncontrolled childhood glaucomas. Ophthalmology(1981) 88:253–258.
   PubMed Web of Science ®Google Scholar
• OLSON RJ, BROMBERT BB, ZIMMERMAN TJ: Apneic spells associated with timolol therapy in a neonate. Am. J. Ophthalmol. (1979) 88(1):120–122.
   PubMed Web of Science ®Google Scholar
• WILLIAMS T, GINTHER WH: Hazards of ophthalmic timolol. N. Engl. J Med. (1982) 306:1485–1486.
   PubMed Web of Science ®Google Scholar
• MORSELLI PL, BOUTROY MJ, BIANCHETTI G et al.: Placental transfer and perinatal pharmacokinetics of betaxolol. Eur. J. Clin. Pharmacol. 1990 38(5):477–483
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, KITAZAWA Y, NOMA A et al.: The effects of beta andrenergic-blocking agents, timolol and carteolol on plasma lipids and lipoproteins in Japanese glaucoma patients. J. Glaucoma (1996) 5:252–277.
   PubMed Web of Science ®Google Scholar
• MCMAHON CD, SCHAFFER RN, HOSKINS HD: Adverse effects experienced by patients taking timolol. Am. J. Ophthalmol. (1979) 88:736–738.
   PubMed Web of Science ®Google Scholar
• TANIGUCHI T, KITAZAWA Y: The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Curr. Opin. Ophthal. (1997) 8(10:55–58.
   PubMedGoogle Scholar
• ••Excellent recent review of side effects of 0-blockers
   Google Scholar
• LYNCH MG, WHITSON JT, BROWN RH et al.: Topical beta-blocker therapy and central nervous system side effects. Arch. Ophthalmol. (1986) 106:908–911.
   Google Scholar
• NELSON WL, FRAUNFELDER FT, SILLS JM et al.: Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1984. Am. J. Ophthalmol. (1986) 102:606–611.
   PubMed Web of Science ®Google Scholar
• WARD R, BEASLEY CH: Effects of topical betaxolol, timolol and placebo on pulmonary function in asthmatic bronchitis. Am.J.Ophthalmol. (1984) 97:86–92.
   PubMed Web of Science ®Google Scholar
• DIGGORY P, CASSELS-BROWN A, VAIL A et al.: Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sypathominietic agents. Lancet (1995) 345:1604–1606.
   PubMed Web of Science ®Google Scholar
• RUSK C, SHARPE E, LAURENCE J et al Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Clin. Ther. (1998) 20(3):454–466.
   Google Scholar
• VUORI ML, ALT MELKHILA T, KAILA T et al.: Plasma andaqueous humor concentrations and systemic effects of topical betaxolol and timolol in man. Acta. Ophthalmol. (1993) 71:201–206.
   PubMed Web of Science ®Google Scholar
• MITTAG TW: Adrenergic and doparninergic drugs inglaucoma. In: The Glaucomas - Glaucoma Therapy. (2nd Edition). Ritch R, Shields MB, Krupin T (Eds.), Mosby, St Louis, USA (1996):1409–1424.
   Google Scholar
• STRAHLMAN E, TIPPING R, VOGEL R: A double-masked,randomized 1-year study comparing dorzolamide (Trusopt), timolol and betaxolol. International Dorzolarnide Study Group. Arch. Ophthalmol. (1995) 113(8):1009–1016.
   PubMed Web of Science ®Google Scholar
• •Multinational comparative study of efficacy and safety in adults.
   Google Scholar
• DICKSTEIN K, AARSLAND T: Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am. J. Ophthalmol. (1996) 121:367–371.
   PubMed Web of Science ®Google Scholar
• PFEIFFER N: Dorzolarnide: development and clinical application of a topical carbonic anhydrase inhibitor. Sun). Ophthalmol. (1997) 42(2):137–147.
   PubMed Web of Science ®Google Scholar
• •An excellent review.
   Google Scholar
• PORTELLOS M, FREEDMAN S, BUCKLEY EG: Efficacy of topical dorzolamide compared with oral acetazola-mide for the treatment of paediatric glaucoma. J. AAPOS. (1998) 2:43–47.
   PubMedGoogle Scholar
• ••Key case series of use of CAI in children.
   Google Scholar
• LIPPA EA, CARLSON LE, EHINGER B et al : Dose responseand duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol (1992) 110(4):495–499.
   PubMedGoogle Scholar
• SILVER H: Clinical efficacy and safety of brinzolarnide(Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolarnide Primary Therapy Study Group. Am. J. Ophthalmol. (1998) 126(3):400–408.
   Google Scholar
• MAUS TL, LARSSON LI, MCLARON JW, BRUBAKER RF: Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch. Ophthalmol. (1997) 115:45–49.
   PubMed Web of Science ®Google Scholar
• MEYER JC, SAMPLES JR: Efficacy of dorzolamide in glaucoma subpopulations including paediatric and secondary glaucomas. Invest. Ophthalmol. Vis. Sci. (1996) 37(Suppl.):1099.
   Google Scholar
• INGRAM CJ, BRUBAKER RF: Effect of brinzolarnide and dorzolamide on aqueous humor flow in human eyes. Am. J. Ophthalmol. (1999) 128(3):292–296.
   PubMed Web of Science ®Google Scholar
• ROSENBERG LF, KRUPIN T, TANIGUCHI T: Combination of systemic acetazolarnide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology (1999) 105:88–93.
   Web of Science ®Google Scholar
• WAYMAN L, LARSSON LI, MAUS T, ALM A, BRUBAKER RF:Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch. Ophthalmol. (1997) 11:1368–1371.
   Google Scholar
• WAYMAN LL, LARSSON LI, MAUS T, BRUBAKER RF: Additive effect of dorzolamide on aqueous humor flow in patient receiving long-term treatment with timolol. Arch. Ophthalmol. (1998) 116(11):1438–1440.
   PubMedGoogle Scholar
• HUTZELMANN J, OWENS S, SHEDDEN A et al.: Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. Br. J. Ophthalmol. (1998) 82:1249–1253.
   PubMed Web of Science ®Google Scholar
• CLINESCHMIDT CM, WILLIAMS RD, SNYDER E et al.: A randomised trial in patients inadequately controlled with timolol alone comparing with dorzolamide - timolol combination to monotherapy with timolol or dorzolamide - dorzolamide - timolol combination study group. Ophthalmology (1998) 105(101952–1959.
   Web of Science ®Google Scholar
• BOYLE JE, GHOSH K, GIESER DK et al.: A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology (1998) 105(10):1946–1951.
   Web of Science ®Google Scholar
• ODBERG T: Dorzolamide-timolol combination versus concomitant administration of its components. Ophthalmology (1999) 106(6):1044–1045.
   PubMed Web of Science ®Google Scholar
• LIPPA EA: Carbonic anyhydrase inhibitors in the glaucomas. In: The Glaucomas - Glaucoma Therapy (2nd Edition). Ritch R, Shields MB, Krupin T. Mosby (Eds.), Mosby, St Louis, USA (1996):1463–1481.
   Google Scholar
• INATANI M, YAMO I: Relationship between acetazola-mide blood concentration and incidence of side effects in glaucomatous patients. J. Ocul. Pharmacol. Ther. (1999) 15(4:97–105
   PubMedGoogle Scholar
• KHAW PT: The childhood g,laucomas: treatment. Paediatric Ophthalmology and Strabismus in the 21st Century. London, UK (2000).
   Google Scholar
• HUTZELMAN JE, POLISAB, MICHAEL AJ et al.: A comparison of the efficacy and tolerability of dorzola-mide and acetazolamide as adjunctive therapy to timolol. Acta. Ophthalmol. (1998) 76(6):717–722
   Web of Science ®Google Scholar
• MAREN TH, CONROY CW, WYNNS GC, LEVY NS: Ocular absorption, blood levels and excretion of dorzola-mide, a topically active carbonic anhydrase inhibitor. J. Ocul. Pharmacol. Ther. (1997) 13(1):23–30.
   PubMed Web of Science ®Google Scholar
• BIOLLAZ J, MUNAFO A, BUCLIN T: Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur. J. Pharmacol. (1995) 47(5):455–460.
   Web of Science ®Google Scholar
• CARLSON J, DURCAN J, ZABRISKIE N, SWARTZ M, CRANDALL A: Nephrolithiasis with dorzolamide. Arch. Ophthalmol. (1999) 117(8):1087–1088.
   PubMedGoogle Scholar
• ZAMBARAKJI HJ, SPENCER AF, VERNON SA: An unusualside effect of dorzolamide. Eye (1997) 11(3):418–419.
   PubMedGoogle Scholar
• KONAWAL A, MORRISON JC, BROWN SVL et al Irreversible corneal decompensation in patients treated with topical dorzolamide. Am. J. Ophthalmol. (1999) 127(4):403–406.
   PubMed Web of Science ®Google Scholar
• TERASHIMA H, SUZUKI K, KATO K, SUGAI N: Membrane-bound carbonic anhydrase activity in the rat corneal endothelium and retina. Jpn. J. Ophthalmol. (1996) 40(2):142–153.
   PubMed Web of Science ®Google Scholar
• LASS JH, KHOSROF SA, LAURENCE JK et al.: A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol and betaxolol. Dorzolamide Corneal Effects Study Group. Arch. Ophthalmol. (1998) 116(8):1003–1010.
   PubMedGoogle Scholar
• ZIAI N, DOLAN JW, KACERE RD, BRUBAKER RF: The effects on aqueous dynamics of PlurA41 a new prosta-glandin F2 alpha analogue after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. (1993) 111:1351–1358.
   PubMed Web of Science ®Google Scholar
• OCKLIND A: Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp. Eye Res. (1998) 67(2):179–191.
   PubMed Web of Science ®Google Scholar
• ANTHONY TL, PIERCE KL, STAMER WD, REGAN JW: Prostaglandin F2 alpha receptors in the human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. (1998) 39(2):315–321.
   PubMed Web of Science ®Google Scholar
• ALM A, STJERNSCHANTZ J, WIDENGARD I: Effects onintraocular pressure and side effects of 0.005% latano-prost applied once daily, evening or morning - a comparison with timolol. Ophthalmology (1995) 102(12):1743–1752.
   Google Scholar
• LINDEN C, ALM A: Latanoprost twice daily is lesseffective than once daily: indication of receptor subsensitivity. Curr. Eye Res. (1998) 17(6):567–572.
   PubMed Web of Science ®Google Scholar
• CAMRAS CB, WAX MB, RITCH R et al.: Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latano-prost Study Group. Am. J. Ophthalmol. (1998) 12(3):390–399.
   Google Scholar
• CAMRAS CB, ALM A, WATSON P et al.: Latanoprost, a prostaglandin analogue for glaucoma therapy - efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology (1996) 103(11):1916–1924.
   PubMed Web of Science ®Google Scholar
• MARTIN L: Clinical experience with latanoprost: a retrospective study of 153 patients. Acta. Ophthalmol. Scand. (1999) 77(3):336–339.
   PubMedGoogle Scholar
• WATSON PG: Latanoprost. Two years' experience of itsuse in the United Kingdom. Latanoprost Study Group. Ophthalmology (1998) 105(1):82–87.
   PubMed Web of Science ®Google Scholar
• KONSTAS AG, MALTEZOS AC, GANDI S et al.: Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am. J. Ophthalmol. (1999) 128(1):15–20.
   PubMed Web of Science ®Google Scholar
• ENYEDI L, FREEDMAN S, BUCKLEY EG: The effectiveness of latanoprost for the treatment of paediatric glaucoma. J. AAPOS (1999) 3(1):33–39.
   PubMed Web of Science ®Google Scholar
• ••Key case series of latanoprost use in children.
   Google Scholar
• ALTUNA JC, GREENFIELD DS, WAND M eta/.: Latanoprostin glaucoma associated with Sturge-Weber syndrome: benefits and side-effects. J. Glaucoma (1 99 9) 8(3):199–203.
   Google Scholar
• YANG CB, FREEDMAN S, MYERS JS et al.: Use of latano-prost in the treatment of glaucoma associated with Sturge-Weber syndrome. Am. J. Ophthalmol. (1998) 126(4):600–602.
   PubMed Web of Science ®Google Scholar
• DIESTELHORST M, ALMEGARD B: Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes. Arch. Clin. Exp. Ophthalmol. (1998) 236(8):577–581.
   PubMed Web of Science ®Google Scholar
• VANLANDIGHAM BD, BRUBAKER RF: Combined effect of dorzolamide and latanoprost on the rate of aqueous humor flow. Am. J. Ophthalmol. (1998) 126(2):191–196.
   PubMed Web of Science ®Google Scholar
• PATELSKA B, GREENFIELD DS, LIEBMANN JM et al.: Latanoprost for uncontrolled glaucoma in a compas-sionate case protocol. Am. J. Ophthalmol. (1997) 124(3):279–286.
   PubMed Web of Science ®Google Scholar
• LINDQUIST NG, LARSSON BS, STJERNSCHANTZ J: Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp. Eye Res. (1999) 69(4):431–436.
   PubMed Web of Science ®Google Scholar
• GRIERSON I, LEE WR, ALBERT DM: The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye colour change. Arch Ophthalmol (1999) 117(3):394–396.
   PubMedGoogle Scholar
• BROWN SM: Increased iris pigment in a child due to latanoprost. Arch. Ophthalmol. (1998) 116:1683–1684.
   PubMedGoogle Scholar
• JOHNSON MA: Hypertrichosis and increased pigmen-tation of eyelashes and adjacent regions of ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am. J. Ophthalmol. (1997) 124:544–547.
   PubMed Web of Science ®Google Scholar
• MOROI SE, GOTTFREDSDOTTIR MS, SCHTEINGART MT et al.: Cystoid macular oedema associated with latano-prost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology (1999) 106(5):1024–1029.
   PubMed Web of Science ®Google Scholar
• FECHTNER R, KHOURI AS, ZIMMERMAN TJ et al.: Anterioruveitis associated with latanoprost. Am. J. Ophthalmol. (1998) 126(1):37–41.
   PubMed Web of Science ®Google Scholar
• WARWAR RE, BULLOCK JD, BALLAL D: Cystoid macularedema and anterior uveitis associated with latano-prost use - experience and incidence in a retrospective review of 94 patients. Ophthalmology (1 99 8) 105(2):263–268.
   Google Scholar
• KAUFMAN HE, VARNELL ED, THOMPSON HW: Latano-prost increases the severity and recurrence of herpetic keratitis in the rabbit. Am. J. Ophthalmol. (1999) 127(5):531–536.
   PubMed Web of Science ®Google Scholar
• WAND M, GILBERT CM, LIESEGANG TJ: Latanoprost andherpes simplex keratitis. Am. J. Ophthalmol. (1999) 127(5):604
   PubMed Web of Science ®Google Scholar
• SUDESH S, COHEN EJ, RAPUANO CJ, WILSON RP: Cornealtoxicity associated with latanoprost. Arch. Ophthalmol. (1999) 117(4):539–540.
   PubMedGoogle Scholar
• ALM A: Prostaglandin derivates as ocular hypotensiveagents. Retin. Eye Res. (1998) 17(3):291–312.
   PubMed Web of Science ®Google Scholar
• LINDEN C, ALM A: Prostaglandin analogues in the treatment of glaucoma. Drugs Aging (1 9 9 9) 14(5):387–398.
   Google Scholar
• HEDNER J, EVERTS B, MOLLER CS: Latanoprost and respiratory function in asthmatic patients. Arch. Ophthalmol. (1999) 117:1305–1309.
   PubMed Web of Science ®Google Scholar
• HEDNER J, SVEDMYR N, LUNDE H, MANDAHL A: The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate steroid-treated asthma. Sum. Ophthalmol. (1997) 47\(Suppl. 2):S5111–S5115.
   Google Scholar
• PEAK AS, SUTTON BM: Systemic adverse effects associ-ated with topical latanoprost. Ann. Pharmacother. (1998) 32(4):504–505.
   PubMed Web of Science ®Google Scholar
• SCHMIDTBORN E: Systemic side effects of latanoprosttherapy in a child with aniridia and glaucoma. Ophthal-mologe (1998) 95(9):633–634. (Abstract only, article in German).
   Google Scholar
• TORTS CB, CAMRAS CB, ZIMMERMAN TJ, YABLONSKI ME: Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am. J. Ophthalmol. (1999) 128:8–14.
   PubMed Web of Science ®Google Scholar
• TORTS CB, TAFOYA ME, CAMRAS CB, YABLONSKI ME: Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology (1995) 102:456–461.
   PubMed Web of Science ®Google Scholar
• TORTS CB, GLEASON ML, CAMRAS CB: Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol. (1995) 113:1514–1517.
   PubMed Web of Science ®Google Scholar
• ROBIN AL, BURNSTEIN Y: Selectivity of site of action and systemic effects of topical alpha agonists. Curr. Opin. Ophthal. (1998) 9:30–33.
   PubMedGoogle Scholar
• •Excellent review.
   Google Scholar
• BURKE J, SCHWARTZ M: Preclinical evaluation of brimonidine. Sum. Ophthalmol. (1996) 41:9–18.
   PubMed Web of Science ®Google Scholar
• SCHADLU R, MAUS T, NAU CB, BRUBAKER RF: Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch. Ophthalmol. (1998) 116(11):1441–1444.
   PubMed Web of Science ®Google Scholar
• SCHUMAN JS: Clinical experience with brimonidine0.2% and timolol 0.5% in glaucoma and ocular hypertension. Sum Ophthalmol. (1996) 41\(Suppl. 1):S27–S37.
   Google Scholar
• WALTERS TR: Development and use of brimonidine intreating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response and dosing studies. Sum. Ophthalmol. (1996) 41\(Suppl. 1):S19–S26.
   Google Scholar
• ROBIN AL: Questions concerning the role of apraclo-nidine in the management of glaucoma. Arch. Ophthalmol. (1995) 113:712–714.
   PubMed Web of Science ®Google Scholar
• GROSS RL, PINYERO A, ORENGONANIA S: Clinical experience with apraclonidine 0.5%. J. Glaucoma (1997) 6(5):298–302.
   Google Scholar
• THOE SWCHWARTZENBERG GW, BUYS YM: Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. Ophthalmology (1999) 106(8)1616–1620.
   Google Scholar
• BUTLER P, MANNSCHRECK M, UN S, HWANG I, ALVARADO J: Clinical experience with the long-term use of 1-percent apraclonidine - incidence of allergic reactions. Arch. Ophthalmol. (1995) 113(3):293–296.
   PubMedGoogle Scholar
• ROBIN AL: The role of alpha agonists in glaucomatherapy. Curr. Opin. Ophthal. (1997) 8(2)42–49.
   Google Scholar
• SCHUMAN JS, HORWITZ B, CHURCH MK et al.: A 1-yearstudy of brimonidine twice daily in glaucoma and ocular hypertension a controlled randomised muhicentred clinical trial. Arch Ophthalmol (1997) 115(7):847–852.
   PubMed Web of Science ®Google Scholar
• GORDON RN, LIEBMANN JM, GREENFIELD DS et al.: Lackof crossover allergic response to brimonidine in patients with known apraclonidine allergy. Eye (1998) 12(4):696–700.
   Google Scholar
• WALTERS TR, TAYLOR RH: Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma. Eye (1999) 13(0:797–798.
   PubMedGoogle Scholar
• DERICK RJ, ROBIN AL, WALTERS TR: Brimonidine tartrate: a one month dose response study. Ophthal-mology (1997) 104:1336.
   Web of Science ®Google Scholar
• JAMPEL HD, ROBIN AL, QUIGLEY HA, POLACK IP: Apraclonidine: a one week dose response study. Arch. Ophthalmol. (1988) 106:1063
   Google Scholar
• GABELT BT, ROBINSON JC, HUBBARD WC et al.: Apraclo-nidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathec-tomized monkeys. Exp. Eye Res. (1994) 59(0:633–644.
   PubMedGoogle Scholar
• ••Demonstrates the high incidence of cardiovascular sideeffects with a adrenergic agonists in monkeys, in contrast to healthy adult humans.
   Google Scholar
• BARNEBEY HS, ROBIN AL, QUIGLEY HA, POLLACK IP: The efficacy of brimonidine on decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology (1993) 100(7):1083–1088
   PubMed Web of Science ®Google Scholar
• MORRISON JC, ROBIN AL: Adjunctive glaucoma therapy: a comparison of apraclonidine to dipivefrin when added to timolol maleate. Ophthalmology (1989) 96(1):3–7
   PubMed Web of Science ®Google Scholar
• DELUISE VP, ANDERSON DR: Primary infantile glaucoma (congenital glaucoma). Sum. Ophthalmol. (1983) 28(1):1–11.
   PubMed Web of Science ®Google Scholar
• JOHNSON DH, EPSTEIN DL, ALLEN RC et al A one year clinical trial of pilocarpine gel. Ophthalmology (1984) 97(6):723–729.
   Web of Science ®Google Scholar
• ••A William R Talbott' & Isabelle Russell-Eggitt2
   Google Scholar